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 INTRODUCTION 
Deferasirox is an iron chelating agent indicated in the 
treatment of chronic iron overload in patients who are 
receiving long term blood transfusions for conditions such as 
beta-thalassemia and other chronic anemias
1
. Its chemical 
name is [4-[(3Z,5E)-3,5-bis(6-oxo-1-cyclohexa-2,4-
dienylidene)-1,2,4-triazolidin -1-yl] benzoic acid
2
. 
Deferasirox is a new tridentate oral iron chelator developed 
by computer remodeling recently approved by FDA for 
children above 2 years. It is the first oral medicat ion 
approved in the USA for this purpose
1
.  Ferric iron has six 
coordination sites, which need to be chelated completely to 
prevent the generation of free radicals. Deferasirox works in  
treating iron toxicity by binding trivalent (ferric) iron (for 
which it has a strong affinity), forming a stable complex 
which is eliminated via the kidneys
1
. Few HPLC and LC 
methods for determination of Deferasirox  were reported in 
the literature review 
5,6,7
 and some reports mainly included 
the determination of Deferasirox in b iological fluids
8,9
. The 
aim of this work is to develop a rapid, economical and 
sensitive RP-HPLC method for identify ing these impurit ies 
at low level is very important. In order to develop a 
robustness method there is an immense need for developing a 
rapid, sensitive and validated analytical method for day- to-
day analysis, in routine analysis in quality control 
laboratories of the drug and which can be even applicable for 
pharmaceutical dosage forms
4
. 
 
Figure 1: Structure of Deferasirox 
MATERIALS AND METHODS  
Materials and reagents  
Deferasirox bulk drug (99.79% purity) and potential 
impurities Salicylic ac id (85.00% purity) & Salicylamide  
(99.38% purity) were provided by quality standard labs. 
Acetonitrile (HPLC grade) were obtained from Merck. 
Instrumentation  
Chromatographic separation was performed with Shimadzu  
LC-2010 high performance liquid chromatography equipped 
with UV variab le wavelength detector.  Chromatograms and 
data were recorded by means of LC solutions software. A 
Mettler Toledo Analytical Balance (XP6), an Ultra Sonicator 
(Bandelin Sonorex EN-200US) was used in the study. 
 
ABSTRACT 
A simple and isocratic reverse phase high performance liquid chromatography (RP-HPLC) method was developed and 
validated for determination of Deferasirox and its impurities. The method was validated as per International Conference on 
Harmonization (ICHQ2A (R1)) guidelines for system suitability, precision, linearity, specificity, solution stability, robustness 
and ruggedness, limit of detection and limit of quantitation. Deferasirox was analyzed by using Inertsil ODS-3V (150 mm X 
4.6 mm, 5 μm) at 35°C column temperature, with isocratic elution. The analysis was performed at a wavelength of 245 nm 
using dual λ absorbance detector. Efficient UV detection at 245 nm enabled determination of Deferasirox without any 
interference of impurities Salicylic acid & Salicylamide.  The retention time (RT) for Deferasirox was around 8.7 min. The 
impurities of Deferasirox are key starting materials. These impurities act as potential impurities. Thus identifying these 
impurities at low level is crucial. The calibration curves were linear over acceptable concentration range. The method 
developed was unique in determining the impurities even at low levels than that of specifications. The developed method was 
successfully applied to estimate the amount of Deferasirox.  
Keywords: Deferasirox, HPLC, RP-HPLC, validation.  
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Preparation of solutions 
Buffer Preparation  
Weigh accurately 1.36 g of potassium di-hydrogen 
orthophosphate in 1000 ml of degassed and filtered Milli-Q-
water and mixed thoroughly. Adjust the PH 3.0±0.05 with 
dilute H3PO4. 
Mobile phase: Buffer: Acetonitrile  (50:50v/v)  
Diluent: Acetonitrile  
Preparation of Deferasirox Standard Solution 
Accurately weighed and transferred about 25 mg of the 
Deferasirox Standard into 50 ml volumetric flask. Dissolved 
in and make up to the volume with diluent. Further dilute 5 
ml of above solution to 25 ml volumetric flask & make upto 
the mark with diluent (0.1mg/ml). 
Preparation of Salicylic acid impurity (impurity-A) 
solution 
Accurately weighed and transferred about 25 mg of the 
Impurity-A into 50 ml volumetric flask. Dissolved in and 
make up to the volume with diluent. Further dilute 5 ml of 
above solution to   25 ml volumetric flask & make  upto the 
mark with diluent (0.1 mg/ml). 
Preparation of Salicylamide impurity (impurity-B) 
solution 
Accurately weighed and transferred about 25 mg of the 
Impurity-B into 50 ml volumetric flask. Dissolved in and 
make up to the volume with diluent. Further dilute 5 ml of 
above solution to   25 ml volumetric flask & make upto the 
mark with diluent (0.1 mg/ml). 
 Method validation                   
The proposed method was validated according to the 
International Conference on Harmonization (ICH) 
guidelines
3
. 
System suitability 
The system suitability was assessed by the duplicate analysis 
of the drug which was spiked by all impurit ies at a 
concentration of 0.1% with respect to the test concentration 
of 0.1 mg/ml. The acceptance criteria were the resolution 
between salicylamide and salicylic acid should not be less 
than 1.5 and tailing factor for Deferasirox peak should not be 
more than 1.5. The theoretical plate count of Deferasirox 
should not be less than 2000. 
Linearity (Calibration curve) 
Level solutions 
A series of solutions in 5 concentrations of 50 %, 80 %, 100 
%, 120 % and 150 % were prepared using the standard stock 
solution (w.r.t 0.1 µg/ml). The linearity of the method was 
demonstrated by above prepared level concentration 50 %, 
80 %, 100 %, 120 % and 150 % of the target concentration of 
0.1 µg/ml. About 10.0 µl of each of the above prepared 
solutions was injected onto the chromatographic s ystem and 
measured. The average peak area response was calculated. 
The acceptance criteria were that the system suitability 
criteria should be meet and % Relative standard deviation for 
area of impurities should not be more than 5.0. The % RSD 
for the peak area of deferasirox in reference solution should 
not be more than 5.0. The regression coefficient for each 
impurity should not be less than 0.99 and % of Y- Intercept 
should be ± 5.0
14.
 
Determination of Limit of Detection and Limit of 
Quantitation  
The limit  of detection and limit of quantificat ion of the 
impurities were determined by calculating the signal-to-noise 
ratio (S/N, i.e., 3.3 for LOD and 10 for LOQ) using the 
following equations designated by International Conference 
on Harmonization (ICH)
3
. 
Calculation 
LOD = 3.3 × σ/S 
LOQ = 10 × σ/S 
Where     σ = standard deviation 
 
PRECIS ION 
The precision was demonstration under three categories.  
System Precision  
Single individual preparation of Deferasirox drug substance 
was prepared with target concentration of about 0.1 mg/ml 
for system precision.   
Procedure  
Injected six replicate inject ions 10.0 µl of above preparation 
into the chromatographic system and recorded the 
chromatograms. The relative standard deviation of the 
replicate inject ions was calculated. 
Method Precision 
Six indiv idual preparations of Deferasirox drug substance 
spiked with impurities were prepared for method Precision. 
Procedure  
Injected 10.0 µl of above preparations into the 
chromatographic system and recorded the chromatograms. 
Calculated the % relative standard deviations for the peak 
area of Deferasirox in reference solution and for the peak 
area of each impurity. 
Intermediate precision [Ruggedness] 
Demonstration of ruggedness was conducted by different 
analysts, systems, columns and in different days under 
similar conditions at different times. Six individual 
preparations of Deferasirox drug substance spiked with 
impurities were prepared and each was analyzed.  
The acceptance criteria for system, method and intermediate 
precision were that the system suitability criteria should be 
meet and the % Relative standard deviation for the peak area 
of Deferasirox in refe rence solution from the six rep licate 
injections should be not more than 5.0 %. The % Relative 
standard deviation for the peak area of each impurity should 
not be more than 5.0 and for Deferasirox should not be more 
than 2.0 %. 
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Solution stability 
The validity of the solutions was demonstrated for a period 
of 48 hrs by injecting the same solution at periodic intervals 
into the chromatographic system and the chromatograms 
were recorded.  
Procedure  
About 10 µl o f the standard solution was injected at 0 hr, 24
th
 
hr and 48
th
 hr into the chromatographic system and recorded 
the peak areas in the chromatograms.  
Calculations 
Observed the areas of the peaks of Deferasirox injected at the 
mentioned time intervals and the relative standard deviation 
of the injections was calculated. 
The acceptance criteria were that the system suitability 
should pass as per the test method at variable conditions and 
% RSD for the peak area of Deferasirox should not be more 
than 2.0.  
Specificity 
The specificity of the method was demonstrated by 
interference check by injecting the diluent blank, Deferasirox 
and impurities solutions to determine whether any peaks in 
the diluent and impurities solutions are co-eluting with 
Deferasirox peaks.                                    
RES ULTS AND DISCUSS ION 
Method development and optimization 
Deferasirox is soluble in methanol and acetonitrile
2
. The 
drug can be separated on a Inertsil ODS-3V column in  
reverse phase HPLC. The optimization of the method 
development was done by isocratic elution.  
The peak shapes and symmetry of Deferasirox and impurit ies 
were good with above isocratic elution and peaks were 
resolved with greater than 1.5 resolution at a isocratic flow 
rate. The method developed was unique in determining the 
impurities even at low levels  than that of specifications. The 
developed method was successfully applied to estimate the 
amount of Deferasirox. 
Optimised chromatographic conditions:  
               Equipment       :  HPLC Shimadzu  
Detector   :  UV-Vis detector 
Column    :  Inertsil ODS-3V: 150 X 4.6 mm; 5 µm         
               Flow rate                         :  1.5 ml/ min 
               Wavelength             :  245 nm 
               In jection volume             :  10 l 
               Column oven temp          :  35ºC 
               Run time                          :  20 min  
               Sample concentration      :  0.1 mg/ml 
 
Figure 2: Blank Chromatogram of Deferasirox 
 
Figure 3:  Optimized Chromatogram of Deferasirox sample spiked with impurities  
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Method Validation 
System Suitability 
Resolution was not less than 1.5, number of theoretical p lates was not less than 2000, and percentage relative standard 
deviation (%RSD) for Peak Area was not more than 2.0 % for Deferasirox peaks. The %RSD of peak area for the drug is 
within  2% indicating the suitability of the system (Table 1). The efficiency of the column as expressed by number of 
theoretical plates and the tailing factor was 0.90. 
Table 1: System suitability studies 
Injections 
Resolution between salicylamide and 
salicylic acid 
Theoretical  plate count Tailing factor  
Inj-1 1.84 2017.03 0.89 
Inj-2 1.77 2180.50 0.92 
Average 1.80 2098.76 0.90 
 
Acceptance criteria 
Resolution was not less than 1.5, number of theoretical 
plates was not less than 2000, and percentage relative 
standard deviation (%RSD) for Peak Area was not more 
than 2.0 % for Deferasirox peaks as per ICH guidelines
3
. 
Linearity 
The calibration curve constructed was evaluated by its 
correlation coefficient. The peak area of the impurities of 
the drug was linear in the range of 0.05 µg/ml to 0.15 
µg/ml. 
 
Figure 4: Calibrat ion curve of salicylamide impurity 
 
Figure 5: Calibrat ion Curve of salicylic acid impurity 
Table 2: Linearity values of salicylamide  
Concentration  Peak area  
0.05 17.92 
0.08 28.55 
0.10 35.64 
0.12 43.29 
0.15 53.55 
 
Table 3: Linearity values of salicylic acid 
Concentration Peak area 
0.05 23.22 
0.08 37.01 
0.10 46.21 
0.12 54.95 
0.15 68.99 
 
Acceptance Criteria 
Coefficient of correlation should be not less than 0.999  
 LOD and LOQ  
The limit of detection and limit of quantification of the 
impurities is determined by taking the slope and intercept 
values from linearity studies. Limit of detection is 
calculated by using the formula LOD = 3.3 X σ/S and limit  
of detection is calculated by using the formula                
LOQ = 10 X σ/S. Limit of detection (LOD) for salicylamide 
was found to be 0.0060 µg/ml and Limit of quantitation 
(LOQ) for salicy lamide was found to be 0.0182 µg/ml and 
LOD for salicylic acid was found to be 0.0028 µg/ml and 
LOQ for salicylic acid was found to be 0.0087 µg/ml. 
Precision 
The precision was demonstration under three categories.  
Saravanan et al                                 Journal of Drug Delivery & Therapeutics; 2012, 2(3): 148-152                                 150 
© 2011, JDDT. All Rights Reserved                                                     ISSN: 2250-1177                                                  CODEN: JDDTAO  
For system precision Single indiv idual preparation of 
Deferasiorx drug substance was prepared and six rep licate 
injections 10.0 µl of above preparation into the 
chromatographic system and the chromatograms were 
recorded. The relat ive standard deviation of the replicate 
injections was calculated. For Method Precision s ix 
individual preparations of Deferasirox drug substance with 
impurities were injected 10.0 µl of above preparations into 
the chromatographic system and the chromatograms were 
recorded. Calcu lated the % Relative standard deviation for 
the peak area of Deferasirox in reference solution and for 
the peak area of each impurity. For ruggedness s ix 
individual preparations of Deferasirox drug substance with 
impurities were prepared and analyzed  by different analysts, 
systems, columns and in different days under similar 
conditions at different times.  
Acceptance criteria 
The % RSD for the area of five standard injections of 
Deferasirox results should not be more than 2%.  
Table 4: System precision of Deferasirox 
No. of Injections  Area (mV*s) 
1 123698.52 
2 124391.26 
3 126397.90 
4 125024.67 
5 126461.02 
Average 125194.67 
Std. Deviat ion 887.4 
% RSD 0.708 
            
Table 5: Method precision of Deferasirox 
No. of 
Injections 
Area (mV*s) 
Deferasirox Impurity-A Impurity-B 
1 121718.52 44.66 35.49 
2 125790.37 44.37 34.44 
3 125229.51 43.48 36.34 
4 126942.31 43.76 35.83 
5 125295.42 44.36 34.86 
6 124867.03 44.12 34.99 
Average 124973.86 44.12 35.16 
Std. Deviat ion 1597 0.399 0.654 
%RSD 1.24 0.90 1.80 
  
Acceptance criteria 
The % RSD for the area six standard injections of Deferasirox spiked with impurities results should not be more than 2%.  
Table 6: Ruggedness 
No. of 
Injections 
Area(mV*s) 
Deferasirox Impurity - A Impurity - B 
1 123628.41 34.49 31.27 
2 121445.21 34.27 32.59 
3 122166.32 33.90 33.96 
4 124297.37 34.05 32.14 
5 124683.62 35.41 32.62 
6 123557.76 35.53 31.70 
Average 123296.31 34.61 32.38 
Std. Deviat ion 1140 0.662 0.47 
%RSD 0.92 1.90 1.48 
 
Acceptance criteria 
The % RSD for the area six standard injections of 
Deferasirox spiked with impurit ies results should not be 
more than 2%. 
 
Solution stability  
The validity of the solutions was demonstrated for a period 
of 48 hrs by injecting the same solution at 0 and 48 hrs 
intervals into the chromatographic system and the 
chromatograms were recorded.  
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Procedure 
About 10 µl of the standard solution was injected at 0 hr, 
24
th
 hr and 48
th
 hr into the chromatographic system and 
recorded the peak areas in the chromatograms.  
Calculations 
Observed the areas of the peaks of Deferasirox injected at 
the mentioned time intervals and the relative standard 
deviation of the injections was calculated.  
Specificity 
The specificity of the method was demonstrated by 
interference check by injecting the diluent blank, 
Deferasirox and impurit ies solutions to determine whether 
any peaks in the diluent and impurities solutions are co-
eluting with Deferasirox peaks. 
Table 7: Stability data 
Sample name  Area(mV*s) 
Deferasirox - init ial solution 124190.90 
Deferasirox - after 24 hrs 126634.02 
Deferasirox – after 48 hrs 156182.25 
Table 8: Specificity of Deferasirox 
S.No. Name  RT[min] Area[mV*s] TP  TF Resolution 
1 Salicylamide  1.6367 17267.3625 2115.0 0.9666 0.0000 
2 Salicylic acid 2.0050 11018.0711 2057.9 0.9784 1.8451 
3 Deferasirox 8.6920 32084.5594 2102.2 0.9925 12.8081 
 
Acceptance criteria 
Resolution was not less than 1.5, number of theoretical 
plates was not less than 2000, and percentage relative 
standard deviation (%RSD) for Peak Area was not more 
than 2.0 % for Deferasirox peaks. 
ROBUS TNESS 
The Robustness studies were performed for the standard 
solutions and were presented in respectively (Table 9, 10 
and 11).  The values are within the limit which showed that 
the developed method is robust. 
Table 9: Robustness studies for Deferasirox standard 
Chromatographic condition Retention time Theoretical  plate count Tailing factor  
Actual condition 8.70 2125 0.99 
Flow rate 1.3 ml min
-
 7.93 1944 0.96 
Flow rate 1.7 ml min
-
 9.08 2202 0.98 
Acetonitrile 45% 8.55 2183 0.97 
Acetonitrile  55% 8.59 2208 0.99 
Column temperature 30ºC 8.81 2110 0.99 
Column temperature 40ºC 8.80 2235 0.97 
Buffer pH 2.8 9.41 2073 0.99 
Buffer pH 3.2 8.44 2035 0.95 
 
Table 10: Robustness studies for impurity - A 
Chromatographic condition Retention time Theoretical  plate count Tailing factor  
Actual condition 2.00 2125 0.97 
Flow rate 1.3 ml min
-
 2.20 2045 0.95 
Flow rate 1.7 ml min
-
 2.18 2287 0.99 
Acetonitrile 45% 2.28 2089 0.93 
Acetonitrile  55% 2.11 2208 0.99 
Column temperature 30ºC 2.31 2100 1.01 
Column temperature 40ºC 2.17 2066 1.00 
Buffer pH 2.8 2.63 2302 0.98 
Buffer pH 3.2 3.37 2777 1.13 
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Table 11: Robustness studies for impurity - B 
Chromatographic condition Retention time Theoretical  plate count Tailing factor  
Actual condition 1.63 2125 0.93 
Flow rate 1.3 ml min
-
 1.55 2044 0.91 
Flow rate 1.7 ml min
-
 1.52 2256 0.98 
Acetonitrile 45% 1.60 2164 0.99 
Acetonitrile  55% 1.48 2018 0.99 
Column temperature 30ºC 1.61 2010 0.86 
Column temperature 40ºC 1.54 2235 1.01 
Buffer pH 2.8 1.63 2099 0.99 
Buffer pH 3.2 1.57 2173 0.92 
 
CONCLUS ION 
A simple and isocratic reverse phase high performance liquid  
chromatography (RP-HPLC) method was developed and 
validated for determination of impurit ies in Deferasirox. The 
method was validated as per International Conference on 
Harmonizat ion (ICHQ2 (R1)) guidelines for system 
suitability, precision, linearity, specificity, solution stability, 
robustness and ruggedness, limit of detection and limit of 
quantitation. Deferasirox was analyzed by using Inertsil 
ODS-3V (150 X 4.6 mm;  5 µm) at 35ºC temperature with 
isocratic elution. The analysis was performed at a 
wavelength of 245 nm using UV-Vis detector. Efficient UV 
detection at 245 nm enabled determination of Deferasirox 
without any interference of impurities Salicylic acid and 
Salicylamide. The retention time (RT) for Deferasirox was 
around 8.7 min.  
The impurit ies are potential impurities. Thus identifying 
these impurit ies at low level is crucial. The calibration curves 
were linear over a concentration range from 0.05 µg/ml to 
0.15 µg/ml. Limit of detection (LOD) for salicy lamide was 
found to be 0.0060 µg/ml and Limit of quantitation (LOQ) 
for salicylamide was found to be 0.0182 µg/ml and LOD for 
salicylic acid was found to be 0.0028 µg/ml and LOQ for 
salicylic acid was found to be 0.0087 µg/ml. The method 
developed was unique in determining the impurit ies even at 
low levels than that of specifications. The developed method 
was successfully applied to estimate the amount of 
Deferasirox.  The proposed RP-HPLC method is precise, 
sensitive, accurate, specific and efficient and can be used in 
routine analysis in quality control laboratories. 
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